Biofrontera (BFRI) Liabilities and Shareholders Equity (2020 - 2026)
Biofrontera (BFRI) posted quarterly Liabilities and Shareholders Equity of $28.6 million for Q4 2025, up 29.24% year-over-year from $22.1 million in Q4 2024, and up 85.3% quarter-over-quarter from $15.4 million in Q3 2025.
Biofrontera (BFRI) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
Biofrontera's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $28.6 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity rose 29.24% year-over-year to $28.6 million; the TTM figure through Dec 2025 stood at $80.7 million (down 6.98% YoY), while the FY2025 annual figure was $28.6 million, up 29.24% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $28.6 million, up from $15.4 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $55.1 million in Q3 2022, with the low at $8000.0 in Q4 2021.
- The 5-year median for Liabilities and Shareholders Equity is $24.6 million (2024), against an average of $29.2 million.
- The sharpest annual moves came in 2021 and 2022: Liabilities and Shareholders Equity plunged 99.97% in 2021, then jumped 635950.0% in 2022.
- Biofrontera's Liabilities and Shareholders Equity stood at $8000.0 in 2021, then surged by 635950.0% to $50.9 million in 2022, then slumped by 45.11% to $27.9 million in 2023, then dropped by 20.88% to $22.1 million in 2024, then climbed by 29.24% to $28.6 million in 2025.
- Business Quant data shows BFRI's Liabilities and Shareholders Equity at $28.6 million in Q4 2025, $15.4 million in Q3 2025, and $20.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Biofrontera | 19.06 Mn | 14.35 Mn | 9.59 Mn | 24.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.06 Mn |
| Dec 31, 2025 | 28.56 Mn |
| Sep 30, 2025 | 15.42 Mn |
| Jun 30, 2025 | 20.14 Mn |
| Mar 31, 2025 | 16.59 Mn |
| Dec 31, 2024 | 22.10 Mn |
| Sep 30, 2024 | 18.52 Mn |
| Jun 30, 2024 | 21.57 Mn |
| Mar 31, 2024 | 24.58 Mn |
| Dec 31, 2023 | 27.93 Mn |
| Sep 30, 2023 | 34.10 Mn |
| Mar 31, 2023 | 41.97 Mn |
| Dec 31, 2022 | 50.88 Mn |
| Sep 30, 2022 | 55.06 Mn |
| Jun 30, 2022 | 53.63 Mn |
| Mar 31, 2022 | 49.20 Mn |
| Dec 31, 2021 | 8,000.00 |
| Sep 30, 2021 | 15.35 Mn |
| Dec 31, 2020 | 24.14 Mn |